NAV

Ammonium trichlorotellurate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Ammonium trichlorotellurate
DrugBank Accession Number
DB17740
Background

Ammonium trichlorotellurate is an investigational compound with anti-tumour 1 and anti-inflammatory properties.2

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 312.04
Monoisotopic: 312.8682844
Chemical Formula
C2H8Cl3NO2Te
Synonyms
  • Ammonium trichloro [dioxoethylene-O,O') tellurium (IV)
  • Ammonium trichloro(dioxyethylene-o,o')tellurium(iv)
  • Ammonium trichlorotellurate
  • Ossirene
External IDs
  • AS 101
  • AS-101
  • AS101
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
708681952A
CAS number
106566-58-9
InChI Key
AXWLPMGUUAIGJK-UHFFFAOYSA-O
InChI
InChI=1S/C2H4Cl3O2Te.H3N/c3-8(4,5)6-1-2-7-8;/h1-2H2;1H3/q-1;/p+1
IUPAC Name
ammonium 2,2,2-trichloro-1,3,2lambda4-dioxatellurolan-2-uide
SMILES
[NH4+].Cl[Te-]1(Cl)(Cl)OCCO1

References

General References
  1. Sredni B, Weil M, Khomenok G, Lebenthal I, Teitz S, Mardor Y, Ram Z, Orenstein A, Kershenovich A, Michowiz S, Cohen YI, Rappaport ZH, Freidkin I, Albeck M, Longo DL, Kalechman Y: Ammonium trichloro(dioxoethylene-o,o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res. 2004 Mar 1;64(5):1843-52. doi: 10.1158/0008-5472.can-03-3179. [Article]
  2. Brodsky M, Yosef S, Galit R, Albeck M, Longo DL, Albeck A, Sredni B: The synthetic tellurium compound, AS101, is a novel inhibitor of IL-1beta converting enzyme. J Interferon Cytokine Res. 2007 Jun;27(6):453-62. doi: 10.1089/jir.2007.0168. [Article]
ChemSpider
21270261
Wikipedia
AS-101

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
2SuspendedTreatmentAcute Myeloid Leukemia / Myelodysplastic Syndrome1
2TerminatedTreatmentAtopic Dermatitis1
2TerminatedTreatmentChemotherapy-Induced Thrombocytopenia1
2Unknown StatusTreatmentAlopecia1
2Unknown StatusTreatmentExternal Genital Warts1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP2.11Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area18.46 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity30.53 m3·mol-1Chemaxon
Polarizability15.8 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at May 03, 2023 16:23 / Updated at July 18, 2023 22:59